The CCL5 was reported to be upregulated in peripheral blood mononuclear cells of AD patients [29, 65], and Aβ42 treatment could increase the expression of CCL5 and its receptor CCR5 in peripheral mononuclear cells [66]. This evidence concerns the gene CCR5 and Alzheimer disease.